Last 12 months
Inside the activity.
0 purchase rows · 116 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 20 |
| Dec 2025 | 0 | 15 |
| Jan 2026 | 0 | 12 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 15 |
| Apr 2026 | 0 | 23 |
| May 2026 | 0 | 22 |
| Jun 2026 | 0 | 6 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 2 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 07, 2019 Filed Dec 11, 2019 02:21 UTC |
JOHNSON BRENTExec. VP of WW Sales and Mktg
|
Tax withholdingCommon Stock | 96 | $22.88 | $2,196.48 |
DisclosureSEC source: 0000898432-19-001430 · form4.xml · nonDerivative · entry 2 JOHNSON BRENT · CIK 0001254747 · Exec. VP of WW Sales and Mktg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,112 Read SEC document |
| December 07, 2019 Filed Dec 11, 2019 02:21 UTC |
JOHNSON BRENTExec. VP of WW Sales and Mktg
|
Exercise / conversionCommon Stock | 393 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000898432-19-001430 · form4.xml · nonDerivative · entry 1 JOHNSON BRENT · CIK 0001254747 · Exec. VP of WW Sales and Mktg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,208 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| December 07, 2019 Filed Dec 11, 2019 02:18 UTC |
ALLEN MONTY KDirector
|
Exercise / conversionRestricted Stock Units · Derivative | 1,968 | $0.00 | $0.00 |
DisclosureSEC source: 0000898432-19-001425 · form4.xml · derivative · entry 3 ALLEN MONTY K · CIK 0001253352 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,969 Underlying: Common Stock · 1,968 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: On December 7, 2018, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2019. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. F4 · derivative.expiration_date: On December 7, 2018, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2019. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| December 07, 2019 Filed Dec 11, 2019 02:18 UTC |
ALLEN MONTY KDirector
|
GrantRestricted Stock Units · Derivative | 4,370 | $0.00 | $0.00 |
DisclosureSEC source: 0000898432-19-001425 · form4.xml · derivative · entry 2 ALLEN MONTY K · CIK 0001253352 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,370 Underlying: Common Stock · 4,370 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Iradimed Corporation's common stock. F3 · derivative.exercise_date: The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2020. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. F3 · derivative.expiration_date: The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2020. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| December 07, 2019 Filed Dec 11, 2019 02:18 UTC |
ALLEN MONTY KDirector
|
Exercise / conversionCommon Stock | 1,968 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000898432-19-001425 · form4.xml · nonDerivative · entry 1 ALLEN MONTY K · CIK 0001253352 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,283 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| December 07, 2019 Filed Dec 11, 2019 02:17 UTC |
McDonnell Leslie LChief Exec Officer & Director
|
GrantRestricted Stock Units · Derivative | 7,284 | $0.00 | $0.00 |
DisclosureSEC source: 0000898432-19-001422 · form4.xml · derivative · entry 1 McDonnell Leslie L · CIK 0001728715 · Chief Exec Officer & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,284 Underlying: Common Stock · 7,284 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Iradimed Corporation's common stock. F2 · derivative.exercise_date: The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in four equal annual installments beginning on December 7, 2020. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. F2 · derivative.expiration_date: The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in four equal annual installments beginning on December 7, 2020. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| December 07, 2019 Filed Dec 10, 2020 02:59 UTC |
Scott Christopher K.CFO & Secretary
|
Tax withholdingCommon Stock | 665 | $24.54 | $16,319.10 |
DisclosureSEC source: 0000898432-20-000871 · form4.xml · nonDerivative · entry 4 Scott Christopher K. · CIK 0001613803 · CFO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,522 Read SEC document |
| December 07, 2019 Filed Dec 10, 2020 02:59 UTC |
Scott Christopher K.CFO & Secretary
|
Tax withholdingCommon Stock | 384 | $24.54 | $9,423.36 |
DisclosureSEC source: 0000898432-20-000871 · form4.xml · nonDerivative · entry 2 Scott Christopher K. · CIK 0001613803 · CFO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,456 Read SEC document |
| December 04, 2019 Filed Dec 6, 2019 20:24 UTC |
McCreery John KChief Operating Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 738 | $0.00 | $0.00 |
DisclosureSEC source: 0000898432-19-001351 · form4.xml · derivative · entry 3 McCreery John K · CIK 0001703458 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,476 Underlying: Common Stock · 738 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: On December 4, 2017, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in four equal annual installments beginning on December 4, 2018. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. F2 · derivative.expiration_date: On December 4, 2017, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in four equal annual installments beginning on December 4, 2018. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| December 04, 2019 Filed Dec 6, 2019 20:24 UTC |
McCreery John KChief Operating Officer
|
Tax withholdingCommon Stock | 180 | $22.28 | $4,010.40 |
DisclosureSEC source: 0000898432-19-001351 · form4.xml · nonDerivative · entry 2 McCreery John K · CIK 0001703458 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,569 Read SEC document |
| December 04, 2019 Filed Dec 6, 2019 20:24 UTC |
McCreery John KChief Operating Officer
|
Exercise / conversionCommon Stock | 738 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000898432-19-001351 · form4.xml · nonDerivative · entry 1 McCreery John K · CIK 0001703458 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,749 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| December 04, 2019 Filed Dec 6, 2019 20:29 UTC |
Waldman Louis S.Controller
|
Exercise / conversionRestricted Stock Units · Derivative | 738 | $0.00 | $0.00 |
DisclosureSEC source: 0000898432-19-001354 · form4.xml · derivative · entry 3 Waldman Louis S. · CIK 0001613666 · Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,476 Underlying: Common Stock · 738 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: On December 4, 2017, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in four equal annual installments beginning on December 4, 2018. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. F2 · derivative.expiration_date: On December 4, 2017, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in four equal annual installments beginning on December 4, 2018. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| December 04, 2019 Filed Dec 6, 2019 20:29 UTC |
Waldman Louis S.Controller
|
Tax withholdingCommon Stock | 180 | $22.28 | $4,010.40 |
DisclosureSEC source: 0000898432-19-001354 · form4.xml · nonDerivative · entry 2 Waldman Louis S. · CIK 0001613666 · Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,563 Read SEC document |
| December 04, 2019 Filed Dec 6, 2019 20:29 UTC |
Waldman Louis S.Controller
|
Exercise / conversionCommon Stock | 738 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000898432-19-001354 · form4.xml · nonDerivative · entry 1 Waldman Louis S. · CIK 0001613666 · Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,743 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| December 04, 2019 Filed Dec 6, 2019 20:27 UTC |
Casey Francis X.VP of Reg. and Qual. Assurance
|
Exercise / conversionRestricted Stock Units · Derivative | 738 | $0.00 | $0.00 |
DisclosureSEC source: 0000898432-19-001353 · form4.xml · derivative · entry 3 Casey Francis X. · CIK 0001613661 · VP of Reg. and Qual. Assurance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,476 Underlying: Common Stock · 738 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: On December 4, 2017, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in four equal annual installments beginning on December 4, 2018. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. F2 · derivative.expiration_date: On December 4, 2017, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in four equal annual installments beginning on December 4, 2018. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| December 04, 2019 Filed Dec 6, 2019 20:27 UTC |
Casey Francis X.VP of Reg. and Qual. Assurance
|
Tax withholdingCommon Stock | 180 | $22.28 | $4,010.40 |
DisclosureSEC source: 0000898432-19-001353 · form4.xml · nonDerivative · entry 2 Casey Francis X. · CIK 0001613661 · VP of Reg. and Qual. Assurance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,563 Read SEC document |
| December 04, 2019 Filed Dec 6, 2019 20:27 UTC |
Casey Francis X.VP of Reg. and Qual. Assurance
|
Exercise / conversionCommon Stock | 738 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000898432-19-001353 · form4.xml · nonDerivative · entry 1 Casey Francis X. · CIK 0001613661 · VP of Reg. and Qual. Assurance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,743 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| December 04, 2019 Filed Dec 6, 2019 20:23 UTC |
Nardi Steven M.VP Manufacturing
|
Exercise / conversionRestricted Stock Units · Derivative | 738 | $0.00 | $0.00 |
DisclosureSEC source: 0000898432-19-001350 · form4.xml · derivative · entry 3 Nardi Steven M. · CIK 0001613663 · VP Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,476 Underlying: Common Stock · 738 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: On December 4, 2017, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in four equal annual installments beginning on December 4, 2018. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. F2 · derivative.expiration_date: On December 4, 2017, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in four equal annual installments beginning on December 4, 2018. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| December 04, 2019 Filed Dec 6, 2019 20:23 UTC |
Nardi Steven M.VP Manufacturing
|
Tax withholdingCommon Stock | 180 | $22.28 | $4,010.40 |
DisclosureSEC source: 0000898432-19-001350 · form4.xml · nonDerivative · entry 2 Nardi Steven M. · CIK 0001613663 · VP Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 558 Read SEC document |
| December 04, 2019 Filed Dec 6, 2019 20:23 UTC |
Nardi Steven M.VP Manufacturing
|
Exercise / conversionCommon Stock | 738 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000898432-19-001350 · form4.xml · nonDerivative · entry 1 Nardi Steven M. · CIK 0001613663 · VP Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 738 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| December 04, 2019 Filed Dec 7, 2019 01:32 UTC |
ALLEN MONTY KDirector
|
Exercise / conversionRestricted Stock Units · Derivative | 3,690 | $0.00 | $0.00 |
DisclosureSEC source: 0000898432-19-001356 · form4.xml · derivative · entry 2 ALLEN MONTY K · CIK 0001253352 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,690 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: On December 4, 2017, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 4, 2018. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. F2 · derivative.expiration_date: On December 4, 2017, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 4, 2018. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| December 04, 2019 Filed Dec 7, 2019 01:32 UTC |
ALLEN MONTY KDirector
|
Exercise / conversionCommon Stock | 3,690 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000898432-19-001356 · form4.xml · nonDerivative · entry 1 ALLEN MONTY K · CIK 0001253352 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,315 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| December 04, 2019 Filed Dec 7, 2019 01:35 UTC |
VUOTO ANTHONYDirector
|
Exercise / conversionRestricted Stock Units · Derivative | 3,690 | $0.00 | $0.00 |
DisclosureSEC source: 0000898432-19-001357 · form4.xml · derivative · entry 2 VUOTO ANTHONY · CIK 0001222060 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,690 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: On December 4, 2017, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 4, 2018. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. F2 · derivative.expiration_date: On December 4, 2017, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 4, 2018. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| December 04, 2019 Filed Dec 7, 2019 01:35 UTC |
VUOTO ANTHONYDirector
|
Exercise / conversionCommon Stock | 3,690 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000898432-19-001357 · form4.xml · nonDerivative · entry 1 VUOTO ANTHONY · CIK 0001222060 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,719 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| December 04, 2019 Filed Dec 7, 2019 01:31 UTC |
Scott Christopher K.Chief Fin. Officer and Sec.
|
Exercise / conversionRestricted Stock Units · Derivative | 2,952 | $0.00 | $0.00 |
DisclosureSEC source: 0000898432-19-001355 · form4.xml · derivative · entry 3 Scott Christopher K. · CIK 0001613803 · Chief Fin. Officer and Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,904 Underlying: Common Stock · 2,952 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: On December 4, 2017, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in four equal annual installments beginning on December 4, 2018. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. F2 · derivative.expiration_date: On December 4, 2017, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in four equal annual installments beginning on December 4, 2018. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| December 04, 2019 Filed Dec 7, 2019 01:31 UTC |
Scott Christopher K.Chief Fin. Officer and Sec.
|
Tax withholdingCommon Stock | 719 | $22.28 | $16,019.32 |
DisclosureSEC source: 0000898432-19-001355 · form4.xml · nonDerivative · entry 2 Scott Christopher K. · CIK 0001613803 · Chief Fin. Officer and Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,204 Read SEC document |
| December 04, 2019 Filed Dec 7, 2019 01:31 UTC |
Scott Christopher K.Chief Fin. Officer and Sec.
|
Exercise / conversionCommon Stock | 2,952 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000898432-19-001355 · form4.xml · nonDerivative · entry 1 Scott Christopher K. · CIK 0001613803 · Chief Fin. Officer and Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,923 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| December 04, 2019 Filed Dec 7, 2019 01:26 UTC |
JOHNSON BRENTExec. VP of WW Sales and Mktg
|
Exercise / conversionRestricted Stock Units · Derivative | 738 | $0.00 | $0.00 |
DisclosureSEC source: 0000898432-19-001352 · form4.xml · derivative · entry 3 JOHNSON BRENT · CIK 0001254747 · Exec. VP of WW Sales and Mktg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,476 Underlying: Common Stock · 738 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: On December 4, 2017, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in four equal annual installments beginning on December 4, 2018. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. F2 · derivative.expiration_date: On December 4, 2017, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in four equal annual installments beginning on December 4, 2018. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| December 04, 2019 Filed Dec 7, 2019 01:26 UTC |
JOHNSON BRENTExec. VP of WW Sales and Mktg
|
Tax withholdingCommon Stock | 291 | $22.28 | $6,483.48 |
DisclosureSEC source: 0000898432-19-001352 · form4.xml · nonDerivative · entry 2 JOHNSON BRENT · CIK 0001254747 · Exec. VP of WW Sales and Mktg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,815 Read SEC document |
| December 04, 2019 Filed Dec 7, 2019 01:26 UTC |
JOHNSON BRENTExec. VP of WW Sales and Mktg
|
Exercise / conversionCommon Stock | 738 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000898432-19-001352 · form4.xml · nonDerivative · entry 1 JOHNSON BRENT · CIK 0001254747 · Exec. VP of WW Sales and Mktg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,106 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| December 03, 2019 Filed Dec 3, 2019 22:43 UTC |
JOHNSON BRENTExec. VP of WW Sales and Mktg
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $0.93 | $0.00 |
DisclosureSEC source: 0000898432-19-001336 · form4.xml · derivative · entry 9 JOHNSON BRENT · CIK 0001254747 · Exec. VP of WW Sales and Mktg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,768 Underlying: Common Stock · 6,000 shares Expires 2022-11-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2019. F5 · derivative.exercise_date: This option, representing a right to purchase a total of 278,408 shares, was granted on November 1, 2012 and vests over 4 years in equal annual installments commencing on the first anniversary of the grant date. Read SEC document |
| December 03, 2019 Filed Dec 3, 2019 22:43 UTC |
JOHNSON BRENTExec. VP of WW Sales and Mktg
|
SaleCommon Stock | 6,000 | $22.48 | $134,880.00 |
DisclosureSEC source: 0000898432-19-001336 · form4.xml · nonDerivative · entry 6 JOHNSON BRENT · CIK 0001254747 · Exec. VP of WW Sales and Mktg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,368 F1 · kind: The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2019. F4 · price: This transaction was executed in multiple trades at prices ranging from $22.25 to $22.74. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 03, 2019 Filed Dec 3, 2019 22:43 UTC |
JOHNSON BRENTExec. VP of WW Sales and Mktg
|
GrantCommon Stock | 6,000 | $0.93 | $5,580.00 |
DisclosureSEC source: 0000898432-19-001336 · form4.xml · nonDerivative · entry 5 JOHNSON BRENT · CIK 0001254747 · Exec. VP of WW Sales and Mktg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,368 F1 · kind: The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2019. Read SEC document |
| December 02, 2019 Filed Dec 3, 2019 22:43 UTC |
JOHNSON BRENTExec. VP of WW Sales and Mktg
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 9,800 | $0.00 Strike: $0.93 | $0.00 |
DisclosureSEC source: 0000898432-19-001336 · form4.xml · derivative · entry 8 JOHNSON BRENT · CIK 0001254747 · Exec. VP of WW Sales and Mktg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,768 Underlying: Common Stock · 9,800 shares Expires 2022-11-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2019. F5 · derivative.exercise_date: This option, representing a right to purchase a total of 278,408 shares, was granted on November 1, 2012 and vests over 4 years in equal annual installments commencing on the first anniversary of the grant date. Read SEC document |
| December 02, 2019 Filed Dec 3, 2019 22:43 UTC |
JOHNSON BRENTExec. VP of WW Sales and Mktg
|
SaleCommon Stock | 9,800 | $21.96 | $215,208.00 |
DisclosureSEC source: 0000898432-19-001336 · form4.xml · nonDerivative · entry 4 JOHNSON BRENT · CIK 0001254747 · Exec. VP of WW Sales and Mktg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,368 F1 · kind: The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2019. F3 · price: This transaction was executed in multiple trades at prices ranging from $21.80 to $22.10. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 02, 2019 Filed Dec 3, 2019 22:43 UTC |
JOHNSON BRENTExec. VP of WW Sales and Mktg
|
GrantCommon Stock | 9,800 | $0.93 | $9,114.00 |
DisclosureSEC source: 0000898432-19-001336 · form4.xml · nonDerivative · entry 3 JOHNSON BRENT · CIK 0001254747 · Exec. VP of WW Sales and Mktg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,168 F1 · kind: The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2019. Read SEC document |
| November 29, 2019 Filed Dec 3, 2019 22:43 UTC |
JOHNSON BRENTExec. VP of WW Sales and Mktg
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $0.93 | $0.00 |
DisclosureSEC source: 0000898432-19-001336 · form4.xml · derivative · entry 7 JOHNSON BRENT · CIK 0001254747 · Exec. VP of WW Sales and Mktg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,568 Underlying: Common Stock · 10,000 shares Expires 2022-11-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2019. F5 · derivative.exercise_date: This option, representing a right to purchase a total of 278,408 shares, was granted on November 1, 2012 and vests over 4 years in equal annual installments commencing on the first anniversary of the grant date. Read SEC document |
| November 29, 2019 Filed Dec 3, 2019 22:43 UTC |
JOHNSON BRENTExec. VP of WW Sales and Mktg
|
SaleCommon Stock | 10,000 | $22.09 | $220,900.00 |
DisclosureSEC source: 0000898432-19-001336 · form4.xml · nonDerivative · entry 2 JOHNSON BRENT · CIK 0001254747 · Exec. VP of WW Sales and Mktg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,368 F1 · kind: The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2019. F2 · price: This transaction was executed in multiple trades at prices ranging from $21.75 to $22.36. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 29, 2019 Filed Dec 3, 2019 22:43 UTC |
JOHNSON BRENTExec. VP of WW Sales and Mktg
|
GrantCommon Stock | 10,000 | $0.93 | $9,300.00 |
DisclosureSEC source: 0000898432-19-001336 · form4.xml · nonDerivative · entry 1 JOHNSON BRENT · CIK 0001254747 · Exec. VP of WW Sales and Mktg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,368 F1 · kind: The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2019. Read SEC document |
| November 27, 2019 Filed Nov 28, 2019 02:27 UTC |
JOHNSON BRENTExec. VP of WW Sales and Mktg
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $0.93 | $0.00 |
DisclosureSEC source: 0000898432-19-001334 · form4.xml · derivative · entry 9 JOHNSON BRENT · CIK 0001254747 · Exec. VP of WW Sales and Mktg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,408 Underlying: Common Stock · 10,000 shares Expires 2022-11-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2019. F5 · derivative.exercise_date: This option, representing a right to purchase a total of 278,408 shares, was granted on November 1, 2012 and vests over 4 years in equal annual installments commencing on the first anniversary of the grant date. Read SEC document |
| November 27, 2019 Filed Nov 28, 2019 02:27 UTC |
JOHNSON BRENTExec. VP of WW Sales and Mktg
|
SaleCommon Stock | 10,000 | $21.96 | $219,600.00 |
DisclosureSEC source: 0000898432-19-001334 · form4.xml · nonDerivative · entry 6 JOHNSON BRENT · CIK 0001254747 · Exec. VP of WW Sales and Mktg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,368 F1 · kind: The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2019. F4 · price: This transaction was executed in multiple trades at prices ranging from $21.75 to $22.40. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 27, 2019 Filed Nov 28, 2019 02:27 UTC |
JOHNSON BRENTExec. VP of WW Sales and Mktg
|
GrantCommon Stock | 10,000 | $0.93 | $9,300.00 |
DisclosureSEC source: 0000898432-19-001334 · form4.xml · nonDerivative · entry 5 JOHNSON BRENT · CIK 0001254747 · Exec. VP of WW Sales and Mktg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,368 F1 · kind: The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2019. Read SEC document |
| November 27, 2019 Filed Dec 4, 2019 21:39 UTC Amendment |
JOHNSON BRENTExec. VP of WW Sales and Mktg
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $0.93 | $0.00 |
DisclosureSEC source: 0000898432-19-001338 · form4.xml · derivative · entry 9 JOHNSON BRENT · CIK 0001254747 · Exec. VP of WW Sales and Mktg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,568 Underlying: Common Stock · 10,000 shares Expires 2022-11-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2019. F5 · derivative.exercise_date: This option, representing a right to purchase a total of 278,408 shares, was granted on November 1, 2012 and vests over 4 years in equal annual installments commencing on the first anniversary of the grant date. Read SEC document |
| November 27, 2019 Filed Dec 4, 2019 21:39 UTC Amendment |
JOHNSON BRENTExec. VP of WW Sales and Mktg
|
SaleCommon Stock | 10,000 | $21.96 | $219,600.00 |
DisclosureSEC source: 0000898432-19-001338 · form4.xml · nonDerivative · entry 6 JOHNSON BRENT · CIK 0001254747 · Exec. VP of WW Sales and Mktg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,368 F1 · kind: The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2019. F4 · price: This transaction was executed in multiple trades at prices ranging from $21.75 to $22.40. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 27, 2019 Filed Dec 4, 2019 21:39 UTC Amendment |
JOHNSON BRENTExec. VP of WW Sales and Mktg
|
GrantCommon Stock | 10,000 | $0.93 | $9,300.00 |
DisclosureSEC source: 0000898432-19-001338 · form4.xml · nonDerivative · entry 5 JOHNSON BRENT · CIK 0001254747 · Exec. VP of WW Sales and Mktg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,368 F1 · kind: The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2019. Read SEC document |
| November 26, 2019 Filed Nov 28, 2019 02:27 UTC |
JOHNSON BRENTExec. VP of WW Sales and Mktg
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $0.93 | $0.00 |
DisclosureSEC source: 0000898432-19-001334 · form4.xml · derivative · entry 8 JOHNSON BRENT · CIK 0001254747 · Exec. VP of WW Sales and Mktg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 266,408 Underlying: Common Stock · 6,000 shares Expires 2022-11-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2019. F5 · derivative.exercise_date: This option, representing a right to purchase a total of 278,408 shares, was granted on November 1, 2012 and vests over 4 years in equal annual installments commencing on the first anniversary of the grant date. Read SEC document |
| November 26, 2019 Filed Nov 28, 2019 02:27 UTC |
JOHNSON BRENTExec. VP of WW Sales and Mktg
|
SaleCommon Stock | 6,000 | $22.65 | $135,900.00 |
DisclosureSEC source: 0000898432-19-001334 · form4.xml · nonDerivative · entry 4 JOHNSON BRENT · CIK 0001254747 · Exec. VP of WW Sales and Mktg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,368 F1 · kind: The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2019. F3 · price: This transaction was executed in multiple trades at prices ranging from $22.50 to $23.13. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 26, 2019 Filed Nov 28, 2019 02:27 UTC |
JOHNSON BRENTExec. VP of WW Sales and Mktg
|
GrantCommon Stock | 6,000 | $0.93 | $5,580.00 |
DisclosureSEC source: 0000898432-19-001334 · form4.xml · nonDerivative · entry 3 JOHNSON BRENT · CIK 0001254747 · Exec. VP of WW Sales and Mktg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,368 F1 · kind: The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2019. Read SEC document |
| November 26, 2019 Filed Dec 4, 2019 21:39 UTC Amendment |
JOHNSON BRENTExec. VP of WW Sales and Mktg
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $0.93 | $0.00 |
DisclosureSEC source: 0000898432-19-001338 · form4.xml · derivative · entry 8 JOHNSON BRENT · CIK 0001254747 · Exec. VP of WW Sales and Mktg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,568 Underlying: Common Stock · 6,000 shares Expires 2022-11-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2019. F5 · derivative.exercise_date: This option, representing a right to purchase a total of 278,408 shares, was granted on November 1, 2012 and vests over 4 years in equal annual installments commencing on the first anniversary of the grant date. Read SEC document |
| November 26, 2019 Filed Dec 4, 2019 21:39 UTC Amendment |
JOHNSON BRENTExec. VP of WW Sales and Mktg
|
SaleCommon Stock | 6,000 | $22.65 | $135,900.00 |
DisclosureSEC source: 0000898432-19-001338 · form4.xml · nonDerivative · entry 4 JOHNSON BRENT · CIK 0001254747 · Exec. VP of WW Sales and Mktg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,368 F1 · kind: The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2019. F3 · price: This transaction was executed in multiple trades at prices ranging from $22.50 to $23.13. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.